Glioblastoma multiforme (GBM) is the most common primary brain tumor and is uniformly fatal. During carcinogenesis, tumor suppressor genes are silenced by aberrant histone deacetylase (HDAC) activity. Reversing this modification has become a goal for tumor therapy. Suberoylanilide hydroxamic acid (SAHA) is an orally-active potent inhibitor of HDAC. This agent may not only help control tumors but also alter cerebral biochemistry to improve depressive symptoms afflicting many GBM patients. An NCI-funded multi-institutional trial for GBM combining SAHA with standard chemoradiation is scheduled to open soon. However, the lack of reliable biomarkers to predict early response severely hampers the treatment of GBM patients with HDAC inhibitors. Magnetic resonance imaging (MRI) is the standard tool for monitoring therapeutic response in GBMs. Although useful, conventional MRI has shortcomings including difficulty at distinguishing true tumor progression from """"""""pseudo-progression"""""""" that is often seen soon after completion of chemoradiation. MRI may also not be ideal for evaluating new therapies, many of which help only a subset of patients. For GBMs, therapeutic response is mainly evaluated by assessing for tumor changes on conventional MRIs, since repeat surgical biopsy is too invasive and may be prone to sampling error. However, this is not ideal for evaluating response to SAHA since our preliminary data indicate that drug response is associated with redifferentiation rather than killing/shrinking tumors, which may normalize cancer cell metabolism. While conventional MRI detects tumor size and location, it cannot detect this type of normalization. We propose to fill this void by using MR spectroscopic imaging (MRSI), which uses special techniques in an MRI scanner to measure the metabolism of cancer cells as well as normal brain. While MRSI is not new, it has not gained widespread clinical use due to poor resolution, long scan times, and difficulty integrating with other types of brain scans. We propose to implement state-of-art MRSI technology that can rapidly generate metabolite maps of the entire brain coupled with introduction of an imaging registration/analysis program that combines MRSI data with other imaging studies in a clinically useful fashion. Our long-term goal is to develop MRSI into a practical clinical tool that can be readily implemented at most institutions. The establishment of reliable MRSI metabolic biomarkers to assess early response would be of great value in developing new treatments, especially those such as SAHA which do not work by simply killing cells. By allowing clinicians to detect normalization of cancer metabolism in as little as one week of therapy, patients destined to benefit from treatment may be reassured, while those not showing a metabolic response can be switched from an ineffective treatment without further wasting of time. This would clearly be a highly innovative use of MRSI. Importantly, in addition to monitoring tumor response to SAHA therapy, our MRSI-based tool will allow assessment of the biochemical content of normal brain, and may thus indirectly monitor the subject's quality-of-life.
Vorinostat, or SAHA, is an orally active, potent inhibitor of aberrant histone deacetylation activity that induces redifferentiation of glioblastoma (GBM) shifting its metabolism towards a more normal brain-like state. In this study, we will establish a important clinical tool (magnetic resonance spectroscopic imaging, or MRSI) to detect changes in tumor metabolite levels soon after initiation of SAHA treatment as a predictor of therapeutic response in GMB patients. Our MRSI-based tool will aid clinicians in identifying early modification of SAHA treatment indicative of favorable response and may allow initiation of alternative therapies at an earlier time if it is clear that SAHA is not effective. The RESUME AND SUMMARY OF DISCUSSION section above documents the final outcome of the evaluation by the review committee and is the basis for the assigned priority score. The comments and criterion scores in the CRITIQUE section below were prepared by the reviewers assigned to this application and are provided without significant modification or editing by staff. These critiques and criterion scores were prepared prior to the meeting and may not have been revised subsequent to the discussion at the review meeting.
|Cordova, J Scott; Gurbani, Saumya S; Holder, Chad A et al. (2016) Semi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided Surgery. Mol Imaging Biol 18:454-62|
|Cordova, J Scott; Gurbani, Saumya S; Olson, Jeffrey J et al. (2016) A systematic pipeline for the objective comparison of whole-brain spectroscopic MRI with histology in biopsy specimens from grade III glioma. Tomography 2:106-116|
|Cordova, James S; Shu, Hui-Kuo G; Liang, Zhongxing et al. (2016) Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol 18:1180-9|
|Jiang, Xiaojun; Fox, Tim; Cordova, James S et al. (2015) Automated Verification of IGRT-based Patient Positioning. J Appl Clin Med Phys 16:5295|
|Shim, Hyunsuk; Wei, Li; Holder, Chad A et al. (2014) Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. AJR Am J Roentgenol 203:W158-65|
|Owonikoko, Taofeek K; Arbiser, Jack; Zelnak, Amelia et al. (2014) Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol 11:203-22|
|Cordova, James S; Schreibmann, Eduard; Hadjipanayis, Costas G et al. (2014) Quantitative tumor segmentation for evaluation of extent of glioblastoma resection to facilitate multisite clinical trials. Transl Oncol 7:40-7|
|Wang, Xin; Salibi, Nouha; Fayad, Laura M et al. (2014) Proton magnetic resonance spectroscopy of skeletal muscle: a comparison of two quantitation techniques. J Magn Reson 243:81-4|
|Schreibmann, Eduard; Crocker, Ian; Schuster, David M et al. (2014) Four-dimensional (4D) motion detection to correct respiratory effects in treatment response assessment using molecular imaging biomarkers. Technol Cancer Res Treat 13:571-82|
|Mountz, James M; Yankeelov, Thomas E; Rubin, Daniel L et al. (2014) Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. J Clin Oncol 32:2115-6|
Showing the most recent 10 out of 11 publications